3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Primary Myelofibrosis
2
Myeloproliferative Disorders
2
Carcinoma, Non-Small-Cell Lung
2
Thrombocytosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polycythemia Vera
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Lymphoma, Mantle-Cell
1
Lung Neoplasms
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Inhibition, Psychological
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Graft vs Host Disease
1
B-cell Malignancies
1
Anemia, Refractory, with Excess of Blasts
1
Interventions
Doxorubicin
5
pembrolizumab
4
Specimen Handling
4
Radiotherapy
4
Radiation
4
Nivolumab
4
Magnetic Resonance Spectroscopy
3
Ipilimumab
3
CTLA-4 Antigen
3
Biopsy
3
cabozantinib
2
Ifosfamide
2
tremelimumab
1
talimogene laherparepvec
1
regorafenib
1
peposertib
1
pazopanib
1
olaratumab
1
liposomal doxorubicin
1
futibatinib
1
fludarabine
1
eribulin
1
durvalumab
1
avelumab
1
aldesleukin
1
X-Rays
1
Trabectedin
1
Standard of Care
1
Quality of Life
1
Injections
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Histiocytoma, Malignant Fibrous
×
INCB039110
×
1 year
×
Clear all
No trials found.